
    
      This is a Phase 2, randomized, investigator and patient-blind, sponsor-unblinded, parallel
      group, placebo-controlled study to investigate the safety, tolerability, PK, and PD of
      ATI-450 plus methotrexate versus methotrexate alone in patients with moderate to severe RA
      with inadequate response to methotrexate. All subjects will be required to complete a safety
      follow up visit 30 days post last study medication administration.
    
  